What is Zacks Small Cap’s Forecast for ABEO Q1 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for Abeona Therapeutics in a report issued on Monday, March 24th. Zacks Small Cap analyst D. Bautz anticipates that the biopharmaceutical company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q2 2025 earnings at ($0.33) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.

Several other equities research analysts have also weighed in on the company. Oppenheimer began coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target on the stock. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $5.00 on Wednesday. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The stock’s 50 day simple moving average is $5.43 and its two-hundred day simple moving average is $5.82. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a market cap of $217.36 million, a price-to-earnings ratio of -1.86 and a beta of 1.79.

Hedge Funds Weigh In On Abeona Therapeutics

Several large investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. grew its position in Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after purchasing an additional 652,366 shares during the last quarter. Western Standard LLC increased its position in shares of Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Jane Street Group LLC raised its holdings in Abeona Therapeutics by 894.8% in the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after acquiring an additional 118,262 shares during the last quarter. 683 Capital Management LLC lifted its position in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after acquiring an additional 116,845 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Abeona Therapeutics during the 4th quarter valued at $520,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.